Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-24 4:16 pm Purchase | 2025-02-14 | 13G | Aardvark Therapeutics, Inc. Common Stock AARD | Decheng Capital Global Life Sciences Fund IV, L.P. | 3,917,299 18.300% | 3,917,299 (New Position) | Filing History |
| 2025-02-14 5:40 pm Purchase | 2024-12-31 | 13G | CG Oncology, Inc. Common stock CGON | Decheng Capital Global Life Sciences Fund IV, L.P. | 6,371,669 8.400% | 912,859 (+16.72%) | Filing History |
| 2025-02-14 5:38 pm Purchase | 2024-12-31 | 13G | Upstream Bio, Inc. UPB | Decheng Capital Global Life Sciences Fund IV, L.P. | 3,285,293 6.100% | 3,285,293 (New Position) | Filing History |
| 2024-04-09 7:12 pm Purchase | 2024-01-29 | 13G | CG Oncology, Inc. Common stock CGON | Decheng Capital Global Life Sciences Fund IV, L.P. | 5,458,810 8.200% | 400,000 (+7.91%) | Filing History |
| 2024-02-08 5:17 pm Purchase | 2024-01-29 | 13G | CG Oncology, Inc. Common stock CGON | Decheng Capital Global Life Sciences Fund IV, L.P. | 5,058,810 7.600% | 5,058,810 (New Position) | Filing History |
| 2021-02-16 5:21 pm Purchase | 2021-02-05 | 13D | Equillium, Inc. EQ | Decheng Capital Global Life Sciences Fund IV, L.P. | 5,733,021 19.700% | 5,733,021 (New Position) | Filing History |